CA
OLMA icon

Clearstead Advisors’s Olema Pharmaceuticals OLMA Stock Holding History

Clearstead Advisors’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-38
Closed -$567 – 3710
2026
Q1 		$567 Sell
38
-5
-12% -$111 ﹤0.01% 2107
2025
Q4 		$1.07K Buy
+43
New +$765 ﹤0.01% 2223

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Clearstead Advisors's OLMA Position: Q2 2026 in Review

Clearstead Advisors sold out of Olema Pharmaceuticals (OLMA) in Q2 2026, closing a stake of 38 shares — an estimated $567 sold.

Clearstead Advisors first reported a position in OLMA in Q4 2025 and held it in 2 quarters. The position peaked at $1.07K in Q4 2025. 185 funds tracked by Wall St. Rank hold OLMA as of Q2 2026.

  • Clearstead Advisors reported no remaining Olema Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Clearstead Advisors sold 38 Olema Pharmaceuticals shares in Q2 2026, an estimated $567.
  • Clearstead Advisors first reported a position in Olema Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Clearstead Advisors's Olema Pharmaceuticals position peaked at $1.07K in Q4 2025.
  • 185 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.